238Pu elimination profiles after delayed treatment with 3, 4, 3LI(1, 2HOPO) in female and male Swiss-Webster mice. (November 2014)

• Record Type: Journal Article
• Authors: An, Dahlia D.; Villalobos, Jonathan A.; Morales-Rivera, Joel A.; Rosen, Chris J.; Bjornstad, Kathleen A.; Gauny, Stacey S.; Choi, Taylor A.; Sturzbecher-Hoehne, Manuel; Abergel, Rebecca J.
• Is Part Of: International journal of radiation biology. Volume 90:Number 11(2014:Nov.)
• Page Start: 1055
• Page End: 1061
• Publication Date: 2014-11
• Subjects: Radiation -- Physiological effect -- Periodicals; Radiobiology -- Periodicals; 571.45
• DOI: 10.3109/09553002.2014.925150
• Languages: English
• ISSNs: 0955-3002

Abstract

<abstract> <title>Abstract</title> <p> <italic>Purpose</italic>: To characterize the dose-dependent and sex-related efficacy of the hydroxypyridinonate decorporation agent 3, 4, 3-LI(1, 2-HOPO) at enhancing plutonium elimination when post-exposure treatment is delayed.</p> <p> <italic>Materials and methods</italic>: Six parenteral dose levels of 3, 4, 3-LI(1, 2-HOPO) from 1–300 μmol/kg were evaluated for decorporating plutonium in female and male Swiss-Webster mice administered a soluble citrate complex of ²³⁸Pu and treated 24 hours later. Necropsies were scheduled at four time-points (2, 4, 8, and 15 days post-contamination) for the female groups and at three time-points (2, 4, and 8 days post-contamination) for the male groups.</p> <p> <italic>Results</italic>: Elimination enhancement was dose-dependent in the 1–100 μmol/kg dose range at all necropsy time-points, with some significant reductions in full body and tissue content for both female and male animals. The highest dose level resulted in slight toxicity, with a short recovery period, which delayed excretion of the radionuclide.</p> <p> <italic>Conclusions</italic>: While differences were noted between the female and male cohorts in efficacy range and recovery times, all groups displayed sustained dose-dependent ²³⁸Pu elimination enhancement after delayed parenteral treatment with 3, 4, 3-LI(1, 2-HOPO), the actinide decorporation agent under development.</p> </abstract>